Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Verona Pharma plc (NASDAQ: VRNA).

Full DD Report for VRNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: VRNA)

Key events next week - healthcare
Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 12:02
Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference
LONDON, May 09, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will present data from it...
Source: GlobeNewswire
Date: May, 09 2018 08:30
Verona Pharma reports Q1 results
Verona Pharma (NASDAQ: VRNA ): Q1 EPS of -3.7p Cash and cash equivalents of £35M Press Release More news on: Verona Pharma plc, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 08 2018 04:18
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
Announced positive top-line data from two Phase 2 clinical trials ahead of schedule Met primary and key secondary endpoints in 403 patient Phase 2b clinical trial for maintenance treatment of COPD Met primary and secondary endpoints in Cystic Fibrosis Phase 2a clinical trial LON...
Source: GlobeNewswire
Date: May, 08 2018 02:00
Verona Pharma to Present at BioEuroquity Europe 2018
LONDON, May 04, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Piers Morgan, Chief Fi...
Source: GlobeNewswire
Date: May, 04 2018 08:30
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018
LONDON, May 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited f...
Source: GlobeNewswire
Date: May, 02 2018 08:30
Verona Pharma Announces Departure of Chief Medical Officer
LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today anno...
Source: GlobeNewswire
Date: April, 11 2018 02:00
Mereo BioPharma Proposes Terms For U.S. IPO
Quick Take Mereo BioPharma ( OTC:MREO ) intends to raise $70 million from the sale of 4 million ADSs in a U.S. IPO and European private placement. The company is developing a pipeline of in-licensed drugs from Novartis ( NVS ) and AstraZeneca ( AZN ). MREO is taking an unorthodox approac...
Source: SeekingAlpha
Date: April, 09 2018 10:54
Mereo BioPharma Group Files For U.S. IPO
Quick Take Mereo BioPharma Group ( MREO ) intends to sell ADSs for gross proceeds of $80.5 million from a U.S. IPO, according to an F-1 registration statement . The firm is a specialty biopharmaceutical company focused on the acquisition and rapid development of innovative medicines t...
Source: SeekingAlpha
Date: March, 27 2018 19:58

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1716.1116.449916.7215.76357,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-151001,1009.0909Cover
2018-08-141,2401,34792.0564Short
2018-08-1330031196.4630Short
2018-08-1014632644.7853Short
2018-08-091,8162,15184.4258Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRNA.


About Verona Pharma plc (NASDAQ: VRNA)

Logo for Verona Pharma plc (NASDAQ: VRNA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: VRNA)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 18 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 29 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 22 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 06 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: January, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: VRNA)

      Daily Technical Chart for (NASDAQ: VRNA)


      Stay tuned for daily updates and more on (NASDAQ: VRNA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: VRNA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of VRNA and does not buy, sell, or trade any shares of VRNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/